MedTrace Logo

Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer

NCT02830282 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2020-02-24

No results posted yet for this study

Summary

This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or radiographic evidence of residual tumor at the completion of chemotherapy.

Conditions

Interventions

OTHER

Blood Collection

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Angela DeMichele, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2018-03-16
Completion
2018-03-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02830282 on ClinicalTrials.gov